- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| RELIEF THERAPEUTICS HOLDING AG ADR Aktie jetzt für 0€ handeln | |||||
| 15.12.25 | Relief Therapeutics und NeuroX fusionieren zu MindMaze Therapeutics | 34 | cash | ||
| 15.12.25 | Adhoc: Relief Therapeutics Holding SA: Relief Therapeutics and NeuroX Complete Business Combination and Form MindMaze Therapeutics | 1.060 | EQS Group (EN) | Relief Therapeutics Holding SA / Key word(s): Mergers & Acquisitions
Relief Therapeutics and NeuroX Complete Business Combination and Form MindMaze Therapeutics
15-Dec-2025 / 07:00 CET/CEST
Release... ► Artikel lesen | |
| 25.11.25 | Relief Therapeutics Publishes Joint Deck Ahead Of NeuroX Merger; Stock Up | 4 | RTTNews | ||
| 25.11.25 | Adhoc: Relief Therapeutics Holding SA: Relief Therapeutics and NeuroX Unveil Joint Presentation and Financial Outlook Ahead of Anticipated Business Combination | 1.259 | EQS Group (EN) | Relief Therapeutics Holding SA / Key word(s): Mergers & Acquisitions
Relief Therapeutics and NeuroX Unveil Joint Presentation and Financial Outlook Ahead of Anticipated Business Combination... ► Artikel lesen | |
| 14.11.25 | Adhoc: Relief Therapeutics Holding SA: Relief Therapeutics Shareholders Approve Business Combination with NeuroX | 3.119 | EQS Group (EN) | Relief Therapeutics Holding SA / Key word(s): AGMEGM
Relief Therapeutics Shareholders Approve Business Combination with NeuroX
14-Nov-2025 / 18:20 CET/CEST
Release of an ad hoc announcement... ► Artikel lesen | |
| 29.10.25 | Relief Therapeutics Shares Surge On Positive Results Of RLF-OD032 Bioequivalent Study | 14 | RTTNews | ||
| 29.10.25 | Adhoc: Relief Therapeutics Holding SA: Relief Therapeutics Announces Positive Results from Pivotal Bioequivalence Study of RLF-OD032 | 1.252 | EQS Group (EN) | Relief Therapeutics Holding SA / Key word(s): Study results
Relief Therapeutics Announces Positive Results from Pivotal Bioequivalence Study of RLF-OD032
29-Oct-2025 / 07:00 CET/CEST
Release... ► Artikel lesen | |
| 24.10.25 | Adhoc: Relief Therapeutics Holding SA: Relief Therapeutics Convenes Extraordinary General Meeting | 1.740 | EQS Group (EN) | Relief Therapeutics Holding SA / Key word(s): AGMEGM
Relief Therapeutics Convenes Extraordinary General Meeting
24-Oct-2025 / 06:59 CET/CEST
Release of an ad hoc announcement pursuant... ► Artikel lesen | |
| 08.10.25 | Adhoc: Relief Therapeutics Holding SA: Relief Therapeutics and NeuroX, Successor to MindMaze, Sign Definitive Agreement for Business Combination | 1.825 | EQS Group (EN) | Relief Therapeutics Holding SA / Key word(s): Mergers & Acquisitions
Relief Therapeutics and NeuroX, Successor to MindMaze, Sign Definitive Agreement for Business Combination
08-Oct-2025... ► Artikel lesen | |
| 14.08.25 | Relief Therapeutics erzielt leicht weniger Verlust im ersten Halbjahr | 825 | Moneycab | Genf - Das Biotechunternehmen Relief Therapeutics hat im ersten Halbjahr 2025 leicht weniger Verlust geschrieben. Die liquiden Mittel erhöhten sich gegenüber Ende 2024. Die gesamten Einnahmen verringerten... ► Artikel lesen | |
| 14.08.25 | Adhoc: Relief Therapeutics Holding SA: Relief Therapeutics Publishes 2025 Half-Year Report | 1.734 | EQS Group (EN) | Relief Therapeutics Holding SA / Key word(s): Half Year Results
Relief Therapeutics Publishes 2025 Half-Year Report
14-Aug-2025 / 07:00 CET/CEST
Release of an ad hoc announcement pursuant... ► Artikel lesen | |
| 11.08.25 | Relief Therapeutics Holding SA: Relief Therapeutics Advances Publication of 2025 Half-Year Report | 601 | EQS Group (EN) | Relief Therapeutics Holding SA
/ Key word(s): Half Year Results
Relief Therapeutics Advances Publication of 2025 Half-Year Report
11.08.2025 / 07:00 CET/CEST
Relief Therapeutics... ► Artikel lesen | |
| 29.07.25 | Relief Therapeutics reports proposed business combination with NeuroX | 21 | Seeking Alpha | ||
| 29.07.25 | Relief Therapeutics Signs Binding Term Sheet For Merger With NeuroX Group | 5 | RTTNews | ||
| 29.07.25 | Adhoc: Relief Therapeutics Holding SA: Relief Therapeutics Announces Proposed Business Combination with NeuroX, successor to MindMaze | 2.014 | EQS Group (EN) | Relief Therapeutics Holding SA / Key word(s): Mergers & Acquisitions
Relief Therapeutics Announces Proposed Business Combination with NeuroX, successor to MindMaze
29-Jul-2025 / 07:00 CET/CEST
Release... ► Artikel lesen | |
| 20.06.25 | Adhoc: Relief Therapeutics Holding SA: Relief Therapeutics Receives FDA Response to QIDP Request for RLF-TD011 | 4.556 | EQS Group (EN) | Relief Therapeutics Holding SA / Key word(s): Miscellaneous
Relief Therapeutics Receives FDA Response to QIDP Request for RLF-TD011
20-Jun-2025 / 07:00 CET/CEST
Release of an ad hoc announcement... ► Artikel lesen | |
| 12.06.25 | Relief Therapeutics Holding SA: Relief Therapeutics Announces Results of Annual General Meeting | 649 | EQS Group (EN) | Relief Therapeutics Holding SA
/ Key word(s): AGMEGM
Relief Therapeutics Announces Results of Annual General Meeting
12.06.2025 / 11:00 CET/CEST
Relief Therapeutics Announces... ► Artikel lesen | |
| 22.05.25 | Adhoc: Relief Therapeutics Holding SA: Relief Therapeutics Receives FDA Rare Pediatric Disease Designation for RLF-TD011 | 5.149 | EQS Group (EN) | Relief Therapeutics Holding SA / Key word(s): Research Update
Relief Therapeutics Receives FDA Rare Pediatric Disease Designation for RLF-TD011
22-May-2025 / 07:00 CET/CEST
Release of... ► Artikel lesen | |
| 15.05.25 | Relief Therapeutics Holding SA: Relief Therapeutics Publishes 2025 Annual General Meeting Agenda | 726 | EQS Group (EN) | Relief Therapeutics Holding SA
/ Key word(s): AGMEGM
Relief Therapeutics Publishes 2025 Annual General Meeting Agenda
15.05.2025 / 07:00 CET/CEST
Relief Therapeutics Publishes... ► Artikel lesen | |
| 10.04.25 | Adhoc: Relief Therapeutics Holding SA: Relief Therapeutics Reports 2024 Financial Results and Provides Corporate Update | 1.678 | EQS Group (EN) | Relief Therapeutics Holding SA / Key word(s): Annual Results
Relief Therapeutics Reports 2024 Financial Results and Provides Corporate Update
10-Apr-2025 / 07:00 CET/CEST
Release of an... ► Artikel lesen |
1 2 Weiter >>
23 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| REVIVE THERAPEUTICS | 0,010 | 0,00 % | Revive Therapeutics Ltd.: Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study | TORONTO, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 294,38 | 0,00 % | Praxis Precision Prices $575 Mln Public Offering At $260/shr | ||
| APOGEE THERAPEUTICS | 77,48 | -1,85 % | Apogee Therapeutics Announces Positive Interim Results from Phase 1b Trial of Zumilokibart (APG777), its Potentially Best-in-Class Anti-IL-13 Antibody, in Patients with Mild-to-Moderate Asthma and Highlights 2026 Anticipated Milestones and ... | Phase 1b interim results of zumilokibart (APG777) in asthma demonstrated rapid and durable suppression of FeNO (key biomarker of Type 2 inflammation) through 16 weeks for all patients - Suppression... ► Artikel lesen | |
| VENTYX BIOSCIENCES | 13,830 | +0,73 % | Ventyx Biosciences und BioAge Labs: Tenbagger-Rendite im No Brainer Club! | Mit Ventyx Biosciences feiert der No Brainer Club eine waschechte Tenbagger-Empfehlung: Nach Übernahmegerüchten springt die Aktie heute im regulären Handel zunächst um rund 30% nach oben, bevor sie... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 29,880 | +1,01 % | Arcutis Biotherapeutics, Inc.: FDA Accepts Supplemental New Drug Application for Arcutis' ZORYVE (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children Ages 2 to 5 | Prescription Drug User Fee Act (PDUFA) target action date set for June 29, 2026If approved, ZORYVE cream 0.3% would be the first and only topical PDE4 inhibitor indicated for plaque psoriasis in children... ► Artikel lesen | |
| MOONLAKE IMMUNOTHERAPEUTICS | 14,350 | 0,00 % | MoonLake Immunotherapeutics AG: MoonLake Immunotherapeutics Announces Positive Outcome from Type B Meeting with U.S. FDA and Announces Investor Day | MoonLake requested a Type B meeting with the U.S. Food and Drug Administration (FDA) to obtain regulatory clarity and discuss the clinical evidence strategy for submission of a Biologic License Application... ► Artikel lesen | |
| VERA THERAPEUTICS | 47,690 | -2,03 % | Vera Therapeutics Announces U.S. FDA Granted Priority Review to Biologics License Application for Atacicept for Treatment of Adults with IgA Nephropathy | FDA assigned PDUFA target action date of July 7, 2026.If approved, atacicept would be the first B cell modulator targeting both BAFF and APRIL for IgAN.Atacicept received FDA Breakthrough Therapy... ► Artikel lesen | |
| ENLIVEN THERAPEUTICS | 23,280 | 0,00 % | Enliven Therapeutics, Inc.: Enliven Reports Positive Initial Phase 1b Data for ELVN-001 in CML and Outlines 2026 Clinical Milestones | Cumulative major molecular response (MMR) rate of 69% by 24 weeks, with 53% of patients achieving MMR by 24 weeks in ongoing randomized Phase 1b cohorts
ELVN-001... ► Artikel lesen | |
| MONTE ROSA THERAPEUTICS | 25,310 | 0,00 % | Monte Rosa Therapeutics, Inc.: Monte Rosa Therapeutics Announces Positive Interim Phase 1 Data of MRT-8102 Demonstrating Profound CRP Reductions in Elevated CVD-risk Subjects | In subjects with elevated cardiovascular disease (CVD) risk, MRT-8102, a NEK7-directed molecular glue degrader in development for the treatment of NLRP3/IL-1/IL-6 driven inflammatory diseases, demonstrated... ► Artikel lesen | |
| COGENT BIOSCIENCES | 35,570 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in NonAdvanced Systemic Mastocytosis | WALTHAM, Mass. and BOULDER, Colo., Dec. 30, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined... ► Artikel lesen | |
| BEAM THERAPEUTICS | 28,000 | 0,00 % | Beam Therapeutics Reports Updated Data from BEACON Phase 1/2 Trial of ristoglogene autogetemcel (risto-cel) Highlighting Durable, Differentiated Profile in Sickle Cell Disease (SCD) at American Society of Hematology (ASH) Annual Meeting | Updated Data from 31 Adult and Adolescent SCD Patients Treated with risto-cel (Formerly BEAM-101) Show Mean Hemoglobin F (HbF) Induction of >60%, Hemoglobin S (HbS) Reduction to Resolution of Anemia... ► Artikel lesen | |
| ALUMIS | 18,170 | 0,00 % | What's Going On With Alumis Stock Thursday? | ||
| QIAGEN | 41,290 | 0,00 % | XFRA CAPITAL ADJUSTMENT INFORMATION - 07.01.2026 | Das Instrument SFTU US83404D1090 SOFTBANK GR.UNS.ADR1/2/ON EQUITY wird cum Kapitalmassnahme gehandelt am 07.01.2026 und ex Kapitalmassnahme am 08.01.2026 The instrument SFTU US83404D1090 SOFTBANK GR.UNS.ADR1/2/ON... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 66,98 | +1,15 % | Cantor Fitzgerald reiterates Structure Therapeutics stock rating at Overweight | ||
| ERASCA | 5,840 | 0,00 % | Erasca stock pulls back after 25% jump, Stifel cites competitor data |
Das Unternehmen RELIEF THERAPEUTICS HOLDING AG ADR kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 1,750 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu RELIEF THERAPEUTICS HOLDING AG ADR finden Sie auf Wallstreet Online.